BioLineRx (NASDAQ:BLRX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a report issued on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th.

BioLineRx Stock Performance

Shares of BLRX stock opened at $0.11 on Monday. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The company has a market capitalization of $8.43 million, a price-to-earnings ratio of -0.48 and a beta of 1.46. BioLineRx has a one year low of $0.08 and a one year high of $1.44. The company’s 50-day moving average is $0.20 and its 200 day moving average is $0.46.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. BioLineRx had a negative net margin of 90.57% and a negative return on equity of 163.37%. Sell-side analysts expect that BioLineRx will post -0.15 EPS for the current fiscal year.

Institutional Investors Weigh In On BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. PVG Asset Management Corp bought a new stake in shares of BioLineRx Ltd. (NASDAQ:BLRX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 123,580 shares of the biotechnology company’s stock, valued at approximately $70,000. PVG Asset Management Corp owned 0.15% of BioLineRx at the end of the most recent quarter. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.